Acasti Pharma Inc ACST

Healthcare

Acasti Pharma Inc. is a Canada-based late-stage biopharma company with drug candidates addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; GTX-102, an oral mucosal spray targeting ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability; and GTX-101, a topical spray, targeting postherpetic neuralgia, a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles). The Company’s clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection.

NDAQ:ACST - Post by User

Acasti Pharma Inc > Francine

<< Previous

Bullboard Posts

Next >>

Comment by Francine01on Mar 26, 2020 3:22pm

268 Views

Post# 30850588

RE:Francine

Hey boozer, I am doing well. I hope the same for you. Obviously, not the best time for any investor from Buffet to me and you. Amarin went from 25$ to 10$ and matinas from 2.50$ to 0,50$. The entire sector is not doing very well. I think around july the SP will be back on trace.

Next week, i am expecting an update on the package to the FDA and a meeting date (Will be most likely a Skype or call).

Also, for your info. I dont have any insider info. Didnt sell a single share since 2 years, only accumulation. My last communication with management was at the shareholders meeting in August.

GLTA

<< Previous

Bullboard Posts

Next >>

A junior copper-gold stock trading at a bargain of monumental proportions